AIM Executive Director Joins Panel on FDA and Patient Centeredness

Last month, AIM Executive Director Cynthia Bens spoke on a panel titled “FDA and Patient Centeredness: A Work in Progress” at the FDA/CMS Summit for Biopharma Executives in Washington, D.C. She was joined by representatives from Parent Project Muscular Dystrophy, the National Alliance for Caregiving, the National Health Council, and Bristol-Myers Squibb. Bens offered insights from AIM’s experience working with FDA to qualify endpoints for sarcopenia and shared her perspective on how FDA can expand its Patient-Focused Drug Development Initiative to incorporate innovative activities being led by patient advocacy organizations and industry. You can learn more about the conference here.